As of May 31, 2025, Isracann Biosciences Inc (IPOT.CN) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Isracann Biosciences Inc's Forward P/E to Peers
To better understand Isracann Biosciences Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Isracann Biosciences Inc (IPOT.CN) | - |
| Ether Capital Corp (ETHC.NE) | 91.40 |
Compared to its competitors, Isracann Biosciences Inc's Forward P/E is difficult to compare due to insufficient data.